期刊
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
卷 39, 期 6, 页码 2129-2140出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/147323001103900609
关键词
CELECOXIB; CYCLOOXYGENASE-2 INHIBITORS; FOLFOX4; COLORECTAL CANCER; CYCLOOXYGENASE-2 (COX-2); EFFICACY; PROGNOSIS
资金
- Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer. A total of 90 patients were randomly divided into two groups: group CF was treated with a combination of celecoxib and the folinic acid-fluorouracil-oxaliplatin (FOLFOX4) regimen; and group F was treated with the FOLFOX4 regimen alone. Immunohistochemical analysis of tumour tissues for cyclooxygenase-2 (COX-2) protein was performed. With regard to short-term efficacy, the response and disease control rates were significantly greater in group CF than group F. A log-rank test showed that the 3-year survival rate was significantly greater in group CF than group F. It was concluded that the addition of celecoxib to the FOLFOX4 regimen increased the short-term efficacy and the 3-year survival rate, and improved the quality of life of patients with advanced colorectal cancer. The antitumour and chemosensitizing effects of celecoxib appeared to be independent of COX-2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据